Development of CMX001 for the treatment of poxvirus infections

Viruses

Volumn 2, Issue 12, 2010, Pages 2740-2762

  Lanier, Randall ^a   Trost, Lawrence ^a   Tippin, Tim ^a   Lampert, Bernhard ^a   Robertson, Alice ^a   Foster, Scott ^a   Rose, Michelle ^a   Painter, Wendy ^a   O'Mahony, Rose ^a   Almond, Merrick ^a   Painter, George ^a  

^a Chimerix Inc   (United States)

Author keywords

Antiviral; Cidofovir; CMX001; DsDNA virus; Smallpox; Variola

Indexed keywords

CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; CIDOFOVIR DIPHOSPHATE; CIDOFOVIR MONOPHOSPHATE; PLACEBO; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANOREXIA; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; DEHYDRATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; EMBRYOTOXICITY; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAXIMUM PLASMA CONCENTRATION; MORBIDITY; MORTALITY; NEPHROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; POXVIRUS INFECTION; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; REVIEW; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; SINGLE DRUG DOSE; SMALLPOX; STOMACH DISEASE; STRUCTURE ANALYSIS; VACCINATION;

ANIMALIA; DNA VIRUSES; HUMAN HERPESVIRUS 5; POXVIRIDAE; VARIOLA; VARIOLA VIRUS;

EID: 79952136133     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2122740     Document Type: Review

References (57)

1. Breman, J.G.; Henderson, D.A. Diagnosis and management of smallpox. N. Engl. J. Med. 2002, 346, 1300-1308.
2. Fenner, F.; Henderson, D.A.; Arita, I.; Jezek, Z.; Ladnyi, I.D. Smallpox and its Eradication; World Health Organization: Geneva, Switzerland, 1988.
3. Meltzer, M.I. Risks and benefits of preexposure and postexposure smallpox vaccination. Emerg. Infect. Dis. 2003, 9, 1363-1370.
4. Tucker, J. Scourge: The Once and Future Threat of Smallpox; Altantic Monthly Press: New York, NY, USA, 2006.
5. Chen, N.; Bellone, C.J.; Schriewer, J.; Owens, G.; Frederickson, T.; Parker, S.; Buller, R.M.L. Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: Pathogenesis, prophylaxis and antiviral therapy. Virology 2010, doi:10.1016/j.virol.2010.10.02. Available online: http://www.sciencedirect.com/science/journal/00426822 (accessed 10 November 2010).
6. Ross, E.M. Pharmacodynamics: Mechanisms of Drug Action and the Relationship Between Drug Concentration and Effect. In Goodman and Gilman's The Pharmacological Basis of Therapeutics; Hardman, J.G., Limbird, L.E., Molinoff, P.B., Ruddon, R.W., Gilman, A.G., Eds.; McGraw-Hill: New York, NY, USA, 1996; pp. 29-42.
7. Balzarini, J.; Naesens, L.; De Clercq, E. New antivirals-Mechanism of action and resistance development. Curr. Opin. Microbiol. 1998, 1, 535-546.
8. Painter, G.R.; Hostetler, K.Y. Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol. 2004, 22, 423-427.
9. Connelly, M.C.; Robbins, B.L.; Fridland, A. Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells. Biochem. Pharmacol. 1993, 46, 1053-1057.
10. Cihlar, T.; Chen, M.S. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol. Pharmacol. 1996, 50, 1502-1510.
11. Chou, S.; Lurain, N.S.; Thompson, K.D.; Miner, R.C.; Drew, W.L. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 2003, 188, 32-39.
12. Kinchington, P.R.; Araullo-Cruz, T.; Vergnes, J.P.; Yates, K.; Gordon, Y.J. Sequence changes in the human adenovirus type 5 DNA polymerase associated with resistance to the broad spectrum antiviral cidofovir. Antivir. Res. 2002, 56, 73-84.
13. Magee, W.C.; Aldern, K.A.; Hostetler, K.Y.; Evans, D.H. Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand. Antimicrob. Agents Chemother. 2008, 52, 586-597.
14. Xiong, X.; Smith, J.L.; Chen, M.S. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. 1997, 41, 594-599.
15. Poxvirus Bioinformatics Resource Center. Available online: http://www.poxvirus.org (accessed on 22 January 2009).
16. Altschul, S.F.; Madden, T.L.; Schaffer, A.A.; Zhang, J.; Zhang, Z.; Miller, W.; Lipman, D.J. Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic. Acids Res. 1997, 25, 3389-3402.
17. Hartline, C.B.; Gustin, K.M.; Wan, W.B.; Ciesla, S.L.; Beadle, J.R.; Hostetler, K.Y.; Kern, E.R. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: Activity against adenovirus replication in vitro. J. Infect. Dis. 2005, 191, 396-399.
18. Williams-Aziz, S.L.; Hartline, C.B.; Harden, E.A.; Daily, S.L.; Prichard, M.N.; Kushner, N.L.; Beadle, J.R.; Wan, W.B.; Hostetler, K.Y.; Kern, E.R. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob. Agents Chemother. 2005, 49, 3724-3733.
19. Christensen, N. Penn State College of Medicine, Hershey, PA, USA. Study report, 2007.
20. Randhawa, P.; Farasati, N.A.; Shapiro, R.; Hostetler, K.Y. Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro. Antimicrob. Agents Chemother. 2006, 50, 1564-1566.
21. Jiang, Z.G.; Cohen, J.; Marshall, L.J.; Major, E.O. Hexadecyloxypropyl-cidofovir, CMX001, suppresses JC virus replication in human fetal brain SVG cell cultures. Antimicrob. Agents Chemother. 2010, 54, 4723-4732.
22. Huggins, J.W.; Baker, R.O.; Beadle, J.R.; Hostetler, K.Y. Orally active ether lipid prodrugs of cidofovir for the treatment of smallpox. Antivir. Res. 2002, 53, A66, abstract 104.
23. Kern, E.R.; Hartline, C.; Harden, E.; Keith, K.; Rodriguez, N.; Beadle, J.R.; Hostetler, K.Y. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 2002, 46, 991-995.
24. Buller, R.M.; Owens, G.; Schriewer, J.; Melman, L.; Beadle, J.R.; Hostetler, K.Y. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 2004, 318, 474-481.
25. Prichard, M.N. University of Alabama, Birmingham, AL, USA. Personal communication by email, 2010.
26. Smee, D.F.; Sidwell, R.W.; Kefauver, D.; Bray, M.; Huggins, J.W. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob. Agents Chemother. 2002, 46, 1329-1335.
27. Kornbluth, R.S.; Smee, D.F.; Sidwell, R.W.; Snarsky, V.; Evans, D.H.; Hostetler, K.Y. Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype. Antimicrob. Agents Chemother. 2006, 50, 4038-4043.
28. Andrei, G.; Gammon, D.B.; Fiten, P.; De Clercq, E.; Opdenakker, G.; Snoeck, R.; Evans, D.H. Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J. Virol. 2006, 80, 9391-9401.
29. Becker, M.N.; Obraztsova, M.; Kern, E.R.; Quenelle, D.C.; Keith, K.A.; Prichard, M.N.; Luo, M.; Moyer, R.W. Isolation and characterization of cidofovir resistant vaccinia viruses. Virol. J. 2008, 5, 58.
30. Gammon, D.B.; Snoeck, R.; Fiten, P.; Krecmerova, M.; Holy, A.; De Clercq, E.; Opdenakker, G.; Evans, D.H.; Andrei, G. Mechanism of antiviral drug resistance of vaccinia virus: Identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs. J. Virol. 2008, 82, 12520-12534.
31. Approval of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible. Code of Federal Regulations, Part 314, Subpart I, Title 21, 2002.
32. Painter, G.R.; Trost, L.C.; Lampert, B.M.; Almond, M.R.; Buller, M.; Kern, E.; Painter, G.P.; Robertson, A.T.; Frazer, N.; O'Mahony, R. CMX001. Anti-smallpox agent, anti-cytomegalovirus agent, viral polymerase inhibitor. Drugs Future 2010, 33, 655-661.
33. Franz, D.R.; Jahrling, P.B.; Friedlander, A.M.; McClain, D.J.; Hoover, D.L.; Bryne, W.R.; Pavlin, J.A.; Christopher, G.W.; Eitzen, E.M., Jr. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997, 278, 399-411.
34. Parker, S.; Siddiqui, A.M.; Painter, G.; Schriewer, J.; Buller, R.M. Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeutics. Viruses 2010, 2, 1918-1932.
35. Buller, R.M.L. Saint Louis University, Saint Louis, MO, USA. Study report, 2009.
36. Parker, S.; Touchette, E.; Oberle, C.; Almond, M.; Robertson, A.; Trost, L.C.; Lampert, B.; Painter, G.; Buller, R.M. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antivir. Res. 2008, 77, 39-49.
37. Quenelle, D.C.; Collins, D.J.; Wan, W.B.; Beadle, J.R.; Hostetler, K.Y.; Kern, E.R. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 2004, 48, 404-412.
38. Adams, M.M.; Rice, A.D.; Moyer, R.W. Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox. J. Virol. 2007, 81, 11084-11095.
39. Westwood, J.C.N.; Boulter, E.A.; Bowen, E.T.W.; Maber, H.B. Experimental respiratory infection with poxviruses. I. Clinical virological and epidemiological studies. Br. J. Exp. Pathol. 1966, 47, 453-465.
40. Rice, A.D.; Adams, M.M.; Wallace, G.; Burrage, A.M.; Lindsey, S.F.; Smith, A.J.; Swetnam, D.; Manning, B.R.; Gray, S.A.; Lampert, B.; Foster, S.; Lanier, R.; Robertson, A.; Painter, G.; Moyer, R.W. Efficacy of CMX001 as a post exposure antiviral in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses 2010, (submitted for publication).
41. Rice, A.D.; Adams, M.M.; Lampert, B.; Foster, S.; Lanier, R.; Robertson, A.; Painter, G.R.; Moyer, R.W. Efficacy of CMX001 as a Prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses 2010, (submitted for publication).
42. Earl, P.L.; Americo, J.L.; Wyatt, L.S.; Eller, L.A.; Whitbeck, J.C.; Cohen, G.H.; Eisenberg, R.J.; Hartmann, C.J.; Jackson, D.L.; Kulesh, D.A.; Martinez, M.J.; Miller, D.M.; Mucker, E.M.; Shamblin, J.D.; Zwiers, S.H.; Huggins, J.W.; Jahrling, P.B.; Moss, B. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 2004, 428, 182-185.
43. Hooper, J.W.; Thompson, E.; Wilhelmsen, C.; Zimmerman, M.; Ichou, M.A.; Steffen, S.E.; Schmaljohn, C.S.; Schmaljohn, A.L.; Jahrling, P.B. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol. 2004, 78, 4433-4443.
44. Huggins, J.W.; Martinez, M.J.; Hartmann, C.J.; Hensley, LE.; Jackson, D.L.; Kefauver, D.F.; Kulesh, D.A.; Larsen, T.; Miller, D.M.; Mucker, E.M.; Shamblin, J.D.; Tate, M.K.; Whitehouse, C.A.; Zwiers, S.H.; Jahrling, P.B. Successful cidofovir treatment of smallpox-like disease in Variola and monkeypox primate models. Antivir. Res. 2004, 62, A57-A56.
45. Marriott, K.A.; Parkinson, C.V.; Morefield, S.I.; Davenport, R.; Nichols, R.; Monath, T.P. Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge. Vaccine 2008, 26, 581-588.
46. Franz, D.R.; Jahrling, P.B.; McClain, D.J.; Hoover, D.L.; Byrne, W.R.; Pavlin, J.A.; Christopher, G.W.; Cieslak, T.J.; Friedlander, A.M.; Eitzen, E.M., Jr. Clinical recognition and management of patients exposed to biological warfare agents. Clin. Lab. Med. 2001, 21, 435-473.
47. Lampert, B.M.; Almond, M.A.; Trost, L.C. Species-dependent pharmacokinetics of CMX001, an orally-available prodrug of cidofovir being developed for treatment of poxvirus infection. In Proceeding of the 47th SOT Annual Meeting, Seattle, WA, USA, 16-20 March 2008.
48. Trost, L.C.; Tippin, T.K.; Anderson, M.A.; Painter, W.P. Compromised renal function does not affect the pharmacokinetics of CMX001 in patients with severe double-stranded DNA virus infections. In Proceeding of the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, USA, 12-15 September 2010.
49. Obach, R.S.; Baxter, J.G.; Liston, T.E.; Silber, B.M.; Jones, B.C.; MacIntyre, F.; Rance, D.J.; Wastall, P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther. 1997, 283, 46-58.
50. Tippin, T.K.; Almond, M.R.; Painter, G.R.; Lampert, B.M. In vitro hepatic metabolism of CMX001, a lipid conjugate of cidofovir. Drug Metab. Rev. 2009, 41 (Supplement 3), 149.
51. Tippin, T.K.; Lampert, B.M.; Robertson, A.; Anderson, M.; Almond, M.R.; Painter, G.R.; Trost, L.C. Differences in monkey and human pharmacokinetics and metabolism of CMX001, a lipid conjugate of cidofovir. Antimicrob. Agents Chemother. 2010, to be submitted for publication.
52. Ho, E.S.; Lin, D.C.; Mendel, D.B.; Cihlar, T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J. Am. Soc. Nephrol. 2000, 11, 383-393.
53. Tippin, T.K.; Lampert, B.M.; Painter, G.P.; Lanier, R. Lipid conjugates of cidofovir and tenofovir, CMX001 and CMX157, are not substrates of human organic anion transporters OAT1 and OAT3. In Proceeding of the American Association of Pharmaceutical Scientists Annual Meeting, New Orleans, LA, USA, 14-18 November 2010.
54. Tippin, T.K.; Lampert, B.; Painter, G.; Lanier, R. CMX001, a lipid conjugate of cidofovir: Lack of human organic anion transporter-mediated uptake in vitro and reduced kidney distribution in mice compared to cidofovir. J. Pharmacol. Exp. Ther. 2010, to be submitted for publication.
55. Florescu, D.F.; Igdon, J.; Pergam, S.A.; Neely, M.; Johnston, C.; Way, S.S.; Sande, J.; Lewinsohn, D.; Guzman-Cottrill, J.; Kurtzberg, J.; Papanicolaou, G.; Graham, M.L.; Painter, W.; Lanier, R.; Mommeja-Marin, H.; Anderson, M.; van der Horst, C. Experience with CMX001, a novel antiviral drug, for adenovirus infections in immunocompromised patients. In Proceeding of the IDSA 48th Annual Meeting, Vancouver, BC, Canada, 21-24 October 2010.
56. Centers for Disease Control and Prevention. Progressive vaccinia in a military smallpox vaccine 2015;United States, 2009. MMWR Morb. Mortal. Wkly. Rep. 2009, 58, 532-536.
57. Painter, W.; Mossad, S.; Siemionow, M.; Eghtesad, B.; Djohan, R.; Papay, F.; Avery, R. First use of CMX001, a novel antiviral drug, for the suppression of cytomegalovirus infection in solid organ transplant patients: A case series. Am. J. Transplant. 2010, 10 (Supplement 4), 211 (Abstract# LB10).